Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CureVac (CVAC) Receivables - Other (2019 - 2025)

Historic Receivables - Other for CureVac (CVAC) over the last 7 years, with Q1 2025 value amounting to $2.2 million.

  • CureVac's Receivables - Other fell 2018.89% to $2.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.2 million, marking a year-over-year decrease of 2018.89%. This contributed to the annual value of $3.0 million for FY2024, which is 46.66% down from last year.
  • CureVac's Receivables - Other amounted to $2.2 million in Q1 2025, which was down 2018.89% from $3.0 million recorded in Q4 2024.
  • CureVac's 5-year Receivables - Other high stood at $8.5 million for Q3 2021, and its period low was $2960.3 during Q1 2023.
  • In the last 5 years, CureVac's Receivables - Other had a median value of $2.8 million in 2024 and averaged $2.6 million.
  • As far as peak fluctuations go, CureVac's Receivables - Other soared by 18994407.29% in 2024, and later plummeted by 2018.89% in 2025.
  • Quarter analysis of 5 years shows CureVac's Receivables - Other stood at $3.1 million in 2021, then dropped by 16.08% to $2.6 million in 2022, then increased by 14.02% to $3.0 million in 2023, then dropped by 0.47% to $3.0 million in 2024, then dropped by 25.5% to $2.2 million in 2025.
  • Its Receivables - Other stands at $2.2 million for Q1 2025, versus $3.0 million for Q4 2024 and $5.7 million for Q2 2024.